Sanofi, COVID-19: One Year Later

Originally published on sanofi.com. Sanofi is No. 28 on the 2020 DIversityInc Top 50 Companies for Diversity list. 

One Year Later: Taking Measures to Ensure Scientific Discovery and Innovation Remain on Pace

One year ago, the World Health Organization declared COVID-19 a pandemic, and life as we knew it changed. As billions around the world retreated to their homes, we had little way to know what the future held. But we knew one thing for sure: we could not afford to lose ground in clinical research, and we had a responsibility to our patients to forge ahead with our efforts to help change the practice of medicine.

One year later, we remain committed to driving research and development forward, and refuse to allow the pace of innovation to lapse. In spite of the many challenges the pandemic has posed, we have worked to ensure optimal clinical trial performance and the advancement of our portfolio of potential first-in-class or best-in-class medicines, while maintaining key clinical and regulatory milestone timelines.

Our development teams have gone to great lengths to ensure patient safety and keep trials running, arranging direct-to-patient shipments of study drugs, supporting telemedicine follow-ups, and establishing remote investigator meetings and site visits. As a result, we’ve kept 95% of patients enrolled in our nearly 400 clinical trials in 2020 while starting 59 additional trials, enrolling a total of 4,000 new participants. We have also intensified our efforts to incorporate patient insights into everything we do, starting with early research. In response to the heightened focus on health disparities and inequities in 2020, we moved quickly to gain strategic alignment between our R&D, corporate social responsibility, and public affairs and patient advocacy teams, to ensure individual patient voices are contributing to the design of our clinical trials today, and in the future.

Our employees have remained flexible, adapting our ways of working and seamlessly shifting to virtual collaboration to minimize delays or interruptions. We have continued our pursuit of smart partnerships and acquisitions throughout the pandemic, to help us deliver the next generation of life-changing medicines. We have set in motion our digital strategy, and the incorporation of real-world evidence into R&D, to accelerate study timelines and registrational projects. And we continue to build and strengthen our partnerships with health authorities and other stakeholders so that priority programs remain on track. At the end of December 2020, our R&D pipeline contained 84 projects, including 33 new molecular entities in clinical development or regulatory review. Twelve Specialty Care projects in the R&D pipeline had also entered Phase 3.

At Sanofi, our dedication to making a difference in patients’ lives has only strengthened since COVID-19 took hold of our world. Our hearts are with all who have been impacted by the pandemic, and they – and all of humankind – are our motivation for pushing further, faster. We are working tirelessly to ensure progress for cutting edge science and to solidify the future of medicine – together.

Latest News

Black renters

New Study Reveals Landlords Consistently Discriminate Against Potential Renters With Black or Hispanic ‘Sounding’ Names

In the largest study of its kind ever conducted, researchers with the National Bureau of Economic Research have uncovered what many people of color already know when hunting for an apartment or home: most landlords consistently discriminate or harbor bias against non-white individuals looking to rent their property.  Bloomberg’s Kelsey…

book banning

American Library Association Documents 155 Attempts at Banning Books About POC or LGBTQ Issues in the Last 6 Months

In a depressing turn for anyone who thought society may have outgrown book burning or censorship of books over the last 100 years, it appears the hate-filled phenomenon is back on the rise, increasing with alarming frequency across the country. CNN’s Nicole Chavez has reported the American Library Association “has…

Novartis Chief Medical Officer John Tsai on Balancing Medical Innovations With Patient Needs

Originally published at novartis.com by Elizabeth Dougherty. John Tsai is Novartis’ Head of Global Drug Development and Chief Medical Officer. Novartis Pharmaceuticals is a DiversityInc Hall of Fame company.   John Tsai’s career as a physician, and now as Head of Global Drug Development and Chief Medical Officer for Novartis, had an unlikely…

Montgomery Mayor Steven Reed

City of Montgomery, Alabama Faces $25,000 State Fine for Changing Street Named After a Confederate Leader

Despite a state law designed to “protect” longstanding Confederate monuments and memorials, the city of Montgomery, Alabama, has decided that it would rather incur a fine than continue going on with a city street named after President of the Confederate States from 1861 to 1865, Jefferson Davis. Kim Chandler of…

Global Diversity

Despite Massive Uptick in Global DEI Initiatives, New Study Reveals Real Change in Corporate Workforces Remains Slow 

Even though DEI as a business imperative continues to grow both in the United States and around the world, a new study has found that many business leaders and executives have merely raised awareness of why diversity, equity and inclusion is important — as opposed to actually making meaningful progress…

Novartis Collaborates With Microsoft To Innovate Medicine Through Data and Artificial Intelligence

Originally published on LinkedIn. Novartis Pharmaceuticals is a DiversityInc Hall of Fame company.   “We are not just discoverers. We actually create molecules that have never been made before.” Says Karin Briner, Head of Global Discovery Chemistry at Novartis Institutes for BioMedical Research (NIBR). By collaborating with Microsoft and augmenting the expertise of our…

Mastercard Announces Launch of Crescent City Card Program in Partnership With New Orleans and MoCaFi

Originally published at mastercard.com. Mastercard ranked No. 5 on The DiversityInc Top 50 Companies for Diversity list in 2021.   New Orleans Mayor LaToya Cantrell was joined by executives from Mastercard, Mobility Capital Finance, Inc. (MoCaFi), and Forward Together New Orleans to announce the Crescent City Card Program. The program involves a…

Mastercard on Supporting Inclusive and Sustainable Urban Development by Expanding Its ‘City Possible’ Network

Originally published at mastercard.com. Mastercard ranked No. 5 on The DiversityInc Top 50 Companies for Diversity list in 2021.   Mastercard has continued to expand its support for addressing urban challenges and inequalities, working with city leaders and partners around the world, through the City Possible™ network and capabilities. The unique solutions…